{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:19:15Z","timestamp":1767453555842,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12890-019-0891-x","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T10:03:24Z","timestamp":1562753004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014\u20132016)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-3069","authenticated-orcid":false,"given":"David Patrick","family":"Kateete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogers","family":"Kamulegeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Kigozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred Ashaba","family":"Katabazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deus","family":"Lukoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sindani Ireneaus","family":"Sebit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hergeye","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Arube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George William","family":"Kasule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Musisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myalo Glen","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derrick","family":"Khumalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses L.","family":"Joloba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"891_CR1","volume-title":"The top 10 causes of death","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO): The top 10 causes of death. 2017 http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/ . 29 May 2017."},{"key":"891_CR2","unstructured":"World Health Organization (WHO): Leading causes of death by economy income group. 2017 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death ."},{"key":"891_CR3","volume-title":"Tuberculosis","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO): Tuberculosis. 2017 http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/ . 29 May 2017."},{"issue":"11","key":"891_CR4","first-page":"301","volume":"55","author":"Centers for Disease Control and Prevention (CDC)","year":"2006","unstructured":"Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55(11):301\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"891_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/trstmh\/trw006","volume":"110","author":"J Manjelievskaia","year":"2016","unstructured":"Manjelievskaia J, Erck D, Piracha S, Schrager L. Drug-resistant TB: deadly, costly and in need of a vaccine. Trans R Soc Trop Med Hyg. 2016;110(3):186\u201391.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"891_CR6","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"Kwonjune J. Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863.","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"5","key":"891_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1128\/AAC.01550-10","volume":"55","author":"PJ Campbell","year":"2011","unstructured":"Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"891_CR8","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1128\/JCM.01257-15","volume":"53","author":"E Tagliani","year":"2015","unstructured":"Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter Study. J Clin Microbiol. 2015;53(9):2961\u20139.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"891_CR9","first-page":"1320","volume":"13","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Yew W. Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]. Int J Tuberc Lung Dis. 2009;13(11):1320\u201330.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"25","key":"891_CR10","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","volume":"94","author":"X Zhao","year":"1997","unstructured":"Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci. 1997;94(25):13991\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"891_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3201\/eid1607.091840","volume":"16","author":"C Wongsrichanalai","year":"2010","unstructured":"Wongsrichanalai C, Varma JK, Juliano JJ, Kimerling ME, MacArthur JR. Extensive drug resistance in malaria and tuberculosis. Emerg Infect Dis. 2010;16(7):1063.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"891_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkr173","volume":"66","author":"PE Almeida Da Silva","year":"2011","unstructured":"Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417\u201330.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"891_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s13205-016-0423-9","volume":"6","author":"S Mustafa","year":"2016","unstructured":"Mustafa S, Javed H, Hashmi J, Jamil N, Tahir Z, Akhtar AM. Emergence of mixed infection of Beijing\/Non-Beijing strains among multi-drug resistant Mycobacterium tuberculosis in Pakistan. 3 Biotech. 2016;6(1):108.","journal-title":"3 Biotech"},{"issue":"5","key":"891_CR14","doi-asserted-by":"publisher","first-page":"e0198091","DOI":"10.1371\/journal.pone.0198091","volume":"13","author":"Edgar Kigozi","year":"2018","unstructured":"Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, Wampande EM, Joloba ML, Kateete DP. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLOS ONE. 2018;13(5):e0198091.","journal-title":"PLOS ONE"},{"key":"891_CR15","doi-asserted-by":"crossref","unstructured":"Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType\u00ae MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev. 2016;(9):1-4.","DOI":"10.1002\/14651858.CD010705.pub3"},{"issue":"8","key":"891_CR16","doi-asserted-by":"publisher","first-page":"e70763","DOI":"10.1371\/journal.pone.0070763","volume":"8","author":"D Lukoye","year":"2013","unstructured":"Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, Kalamya JN, Awor A, Date A, Joloba ML. Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National Survey. PLoS One. 2013;8(8):e70763.","journal-title":"PLoS One"},{"issue":"1","key":"891_CR17","doi-asserted-by":"publisher","first-page":"e16130","DOI":"10.1371\/journal.pone.0016130","volume":"6","author":"D Lukoye","year":"2011","unstructured":"Lukoye D, Cobelens FGJ, Ezati N, Kirimunda S, Adatu FE, Lule JK, Nuwaha F, Joloba ML. Rates of Anti-Tuberculosis Drug Resistance in Kampala-Uganda Are Low and Not Associated with HIV Infection. PLoS One. 2011;6(1):e16130.","journal-title":"PLoS One"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12889-015-1614-8","volume":"15","author":"D Lukoye","year":"2015","unstructured":"Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, Gomez GB. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;15:291.","journal-title":"BMC Public Health"},{"issue":"9","key":"891_CR19","doi-asserted-by":"publisher","first-page":"e0185105","DOI":"10.1371\/journal.pone.0185105","volume":"12","author":"BM Musa","year":"2017","unstructured":"Musa BM, Adamu AL, Galadanci NA, Zubayr B, Odoh CN, Aliyu MH. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2017;12(9):e0185105.","journal-title":"PLoS One"},{"issue":"1","key":"891_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3201\/eid1801.110850","volume":"18","author":"E Sanchez-Padilla","year":"2012","unstructured":"Sanchez-Padilla E, Dlamini T, Ascorra A, R\u00fcsch-Gerdes S, Tefera ZD, Calain P, de la Tour R, Jochims F, Richter E, Bonnet M. High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009\u20132010. Emerg Infect Dis. 2012;18(1):29\u201337.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"891_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3201\/eid1903.121287","volume":"19","author":"I Sindani","year":"2013","unstructured":"Sindani I, Fitzpatrick C, Falzon D, Suleiman B, Arube P, Adam I, Baghdadi S, Bassili A, Zignol M. Multidrug-Resistant Tuberculosis, Somalia, 2010\u20132011. Emerg Infect Dis. 2013;19(3):478\u201380.","journal-title":"Emerg Infect Dis"},{"key":"891_CR22","volume-title":"Global tuberculosis report 2016","author":"World Health Organization (WHO)","year":"2016","unstructured":"World Health Organization (WHO): Global tuberculosis report 2016. 2016."},{"key":"891_CR23","volume-title":"Tuberculosis country profile \u2013Uganda","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO): Tuberculosis country profile \u2013Uganda. 2017 https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=\/WHO_HQ_Reports\/G2\/PROD\/EXT\/TBCountryProfile&ISO2=UG&outtype=PDF ."},{"key":"891_CR24","volume-title":"Tuberculosis country profile \u2013Eswatini","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO): Tuberculosis country profile \u2013Eswatini. 2017 https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=\/WHO_HQ_Reports\/G2\/PROD\/EXT\/TBCountryProfile&ISO2=SZ&outtype=pdf ."},{"key":"891_CR25","volume-title":"Tuberculosis country profile \u2013Somalia","author":"World Health Organization (WHO)","year":"2017","unstructured":"World Health Organization (WHO): Tuberculosis country profile \u2013Somalia. 2017 https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=\/WHO_HQ_Reports\/G2\/PROD\/EXT\/TBCountryProfile&ISO2=so&outtype=pdf ."},{"key":"891_CR26","volume-title":"Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO): Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. 2018."},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/1-59259-147-7:019","volume-title":"Mycobacterium tuberculosis Protocols","author":"PD van Helden","year":"2001","unstructured":"van Helden PD, Victor TC, Warren RM, van Helden EG. Isolation of DNA from Mycobacterium tubercolosis. In: Parish T, Stoker NG, editors. Mycobacterium tuberculosis Protocols. Totowa: Humana Press; 2001. p. 19\u201330."},{"issue":"11","key":"891_CR28","first-page":"1262","volume":"10","author":"J Muhumuza","year":"2006","unstructured":"Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi P, Whalen C, Mugerwa RD, Boom H, Eisenach KD, Joloba ML. Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis. 2006;10(11):1262\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"891_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1756-0500-4-280","volume":"4","author":"L Nabyonga","year":"2011","unstructured":"Nabyonga L, Kateete DP, Katabazi FA, Odong PR, Whalen CC, Dickman KR, Joloba ML. Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among pulmonary TB patients in Kawempe municipality, Uganda, using MIRU-VNTR. BMC Res Notes. 2011;4:280.","journal-title":"BMC Res Notes"},{"issue":"12","key":"891_CR30","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/molbev\/mst197","volume":"30","author":"K Tamura","year":"2013","unstructured":"Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30(12):2725\u20139.","journal-title":"Mol Biol Evol"},{"issue":"6","key":"891_CR31","doi-asserted-by":"publisher","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","volume":"50","author":"P Miotto","year":"2017","unstructured":"Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks Angela M, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50(6):1701354.","journal-title":"Eur Respir J"},{"issue":"6","key":"891_CR32","doi-asserted-by":"publisher","first-page":"e39754","DOI":"10.1371\/journal.pone.0039754","volume":"7","author":"S Malik","year":"2012","unstructured":"Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations. PLoS One. 2012;7(6):e39754.","journal-title":"PLoS One"},{"issue":"4","key":"891_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/jac\/dkr566","volume":"67","author":"F Maruri","year":"2012","unstructured":"Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819\u201331.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"891_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12879-014-0703-0","volume":"14","author":"N Ezati","year":"2014","unstructured":"Ezati N, Lukoye D, Wampande EM, Musisi K, Kasule GW, Cobelens FGJ, Kateete DP, Joloba ML. The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda. BMC Infect Dis. 2014;14(1):703.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"891_CR35","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1128\/AAC.02338-13","volume":"58","author":"D Lukoye","year":"2014","unstructured":"Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe BB, Okee M, Joloba ML, Cobelens FGJ. The T2 Mycobacterium tuberculosis Genotype, Predominant in Kampala, Uganda, Shows Negative Correlation with Antituberculosis Drug Resistance. Antimicrob Agents Chemother. 2014;58(7):3853\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"891_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1128\/AAC.01228-13","volume":"58","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014;58(1):364\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"891_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","volume":"3","author":"AS Ginsburg","year":"2003","unstructured":"Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432\u201342.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"891_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1201-9712(02)90136-0","volume":"6","author":"AS Lee","year":"2002","unstructured":"Lee AS, Tang LL, Lim IH, Wong SY. Characterization of pyrazinamide and ofloxacin resistance among drug-resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis. 2002;6(1):48\u201351.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"891_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.diagmicrobio.2012.03.025","volume":"73","author":"C Zhu","year":"2012","unstructured":"Zhu C, Zhang Y, Shen Y, Siu GKH, Wu W, Qian X, Deng G, Xu Y, Lau R, Fan X. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis. 2012;73(3):260\u20133.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"891_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijmyco.2012.08.001","volume":"1","author":"S Rosales-Klintz","year":"2012","unstructured":"Rosales-Klintz S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia L, Merza MA, Muntean I, Bwanga F, et al. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions. Int J Mycobacteriol. 2012;1(3):124\u201330.","journal-title":"Int J Mycobacteriol"},{"issue":"9","key":"891_CR41","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1128\/JCM.00670-16","volume":"54","author":"R Singhal","year":"2016","unstructured":"Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, Myneedu VP, Strong M, Salfinger M. Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India. J Clin Microbiol. 2016;54(9):2298\u2013305.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"891_CR42","doi-asserted-by":"publisher","first-page":"e0120470","DOI":"10.1371\/journal.pone.0120470","volume":"10","author":"E Avalos","year":"2015","unstructured":"Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T. Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A Systematic Review. PLoS One. 2015;10(3):e0120470.","journal-title":"PLoS One"},{"issue":"Pt 1","key":"891_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","volume":"62","author":"EY Nosova","year":"2013","unstructured":"Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol. 2013;62(Pt 1):108\u201313.","journal-title":"J Med Microbiol"},{"issue":"5","key":"891_CR44","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jac\/dkt535","volume":"69","author":"S Feuerriegel","year":"2014","unstructured":"Feuerriegel S, Koser CU, Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother. 2014;69(5):1205\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"891_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7883\/yoken.65.72","volume":"65","author":"H Kim","year":"2012","unstructured":"Kim H, Nakajima C, Kim YU, Yokoyama K, Suzuki Y. Influence of lineage-specific amino acid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. Jpn J Infect Dis. 2012;65(1):72\u20134.","journal-title":"Jpn J Infect Dis"},{"issue":"5","key":"891_CR46","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jac\/dkm038","volume":"59","author":"AN Umubyeyi","year":"2007","unstructured":"Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, De Rijk P, Struelens M, Portaels F. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother. 2007;59(5):1031\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"891_CR47","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/ng.3704","volume":"48","author":"David Stucki","year":"2016","unstructured":"Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, et al. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016;48(12):1535\u201343.","journal-title":"Nature Genetics"},{"issue":"1","key":"891_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","volume":"50","author":"A Aubry","year":"2006","unstructured":"Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother. 2006;50(1):104\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"891_CR49","first-page":"317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel, Switzerland). 2014;3(3):317\u201340.","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"4","key":"891_CR50","doi-asserted-by":"publisher","first-page":"e95083","DOI":"10.1371\/journal.pone.0095083","volume":"9","author":"A Aubry","year":"2014","unstructured":"Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaitre N. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One. 2014;9(4):e95083.","journal-title":"PLoS One"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-0891-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:08:01Z","timestamp":1663942081000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-0891-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-0891-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Higher Degrees Research and Ethics Committee of the School of Biomedical Sciences, Makerere University College of Health Sciences. This committee permitted the use of archived <i>M. tuberculosis<\/i> isolates from patients who participated in the Drug Resistance Surveys that investigated the phenotypic levels and patterns of resistance to first- and second-line anti-TB drugs among new and previously treated sputum smear-positive pulmonary TB patients in Uganda, Somalia and eSwatini. The national\/sub-national drug resistance surveys obtained written informed consent (or assent, where applicable) from all the participants for sample storage and use of stored samples in further studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}